Adj. Assistant Professor. Dr. Dinesh Visva Gunasekeran MBBS, PhD  is a licensed general practitioner (GP) in Singapore with a passion for sustainable initiatives that improve the quality, affordability, and accessibility of healthcare. Dr. Dinesh has managed complex initiatives from health promotion/community-based screening programs in underprivileged populations, to multinational health technology research spanning across industries, by leading multidisciplinary teams to execute aligned objectives. He was conferred the NUS Student Leadership award for multidisciplinary collaborations across faculties of Medicine, Nursing, Pharmacy and others to organise technology-enabled grassroots health promotion campaigns and free annual health screenings for underprivileged communities in Kallang, Geylang, Chinatown, and Macpherson.

Link to more details -  FACES OF CO-OPERATORS: DR DINESH VISVA GUNASEKERAN, A FRONTLINER WITH A VISION 

Awards:  
1. 2019 NUS Young Alumnus (Medicine) of the Year, National University of Singapore (NUS); 
2. Commonwealth Fellow (Innovation), British High Commission (BHC), Singapore; 
3. National Youth Fund award, National Youth Council (NYC), Singapore.
4. Best Paper Award (Education), issued by Singapore General Hospital (SGH) at the  Singhealth DUKE-NUS Congress 2018. 
5. Best Paper award (1st Runner up), issued by  Tan Tock Seng Hospital at the 2018 International Ophthalmology Congress (IOC), Singapore  
6. WHBRS Distinction award 2014 (Open Category), issued by Wong Hock Boon Research Symposium (WHBRS), Singapore. 
7. 2014 TTSH IOC 1st Place (Open Category) award, issued by Tan Tock Seng Hospital (TTSH) at the 7th International Ophthalmology Congress (IOC) by NHGEI, TTSH. 
8. NUS Student Leadership Award (Individual Leadership category)

10 recent publications out of >50:
1) Gunasekeran DV. Technology and chronic disease management. Lancet Diabetes Endocrinol. 2018 Feb;6(2):91. Article.
2) Gunasekeran DV. Invited Commentary: Treating the Patient with Uveitis as an Individual – Not a Disease. JAMA Ophthalmol. 2019;137(2):206-207. Article.
3)  Gunasekeran DV* and Liu ZH*, Tan WJ, Koh J, Cheong CP, Tan LH, Lau CS, Phuah GK, Manuel ND, Chia CC, Seng GS, Tong N, Huin MH, Dulce SV, Yap S, Ponampalam K, Ying H, Ong MEH, R P. Safety and Efficacy of telereview in patients with Abdominal Pain Using Video Consultation: a randomised controlled trial evaluating digital telereview (SAVED). J Med Internet Res. e-pub ahead of print. Article.
4)  Weiling LL, Ming Kai AC, Gunasekeran DV. Digital health for patients with chronic pain during the COVID-19 pandemic. Br J Anaesth. 2020 Aug 10. Epub ahead of print. Article.
5) Gunasekeran DV, Wong TY. Artificial Intelligence in Ophthalmology in 2020: A Technology on the Cusp for Translation and Implementation. Asia Pac J Ophthalmol. 2020;9(2):61-66. Article.
6)  DS Ting, Gunasekeran DV, Wickham L, TY Wong. Next generation telemedicine platforms to screen and triage. Br J Ophthalmol. e-pub ahead of print. Article.
7)  Agrawal R* and Gunasekeran DV*, Grant R, Agarwal A, Onn MK, Nguyen QD, Pavesio C, Gupta V, COTS-1 Study Group. Clinical features and outcomes of patients with TB uveitis treated with anti-tubercular therapy (ATT) in COTS-1. JAMA Ophthalmol. 2017 Dec;135(12):1318-1327. Article.
8)  Z Liu, M Ng, DV Gunasekeran, H Li, K Ponampalam, R Ponampalam. Mobile technology: Usage and perspective of patients and caregivers presenting to a tertiary care emergency. World J Emerg Med. 2020;11(1):5-11. Article.
9)  Chia KJW, Gunasekeran DV, Laude A. The Impact of Switching Anti-Vascular Endothelial Growth Factor Therapy in the Management of Exudative Age-Related Macular Degeneration. Ophthalmic Surg Lasers Imaging Retina. 2017 Oct;48(10):859-869. Article.
10)  Bansal S, Gunasekeran DV, Ang B, Lee J, Khandelwal R, Sullivan P, Agrawal R. Controversies in Pathology and Management of Hyphema. Surv Ophthalmol. 2016 May-Jun;61(3):297-308. Article. 

CHAS, Healthier SG, Cigna, MHC, etc

DVG reports equity investment in AskDr, Doctorbell (acquired by Mobile Health Network Solutions, NYSE:$MNDR), Healthlink Protocol, and VISRE.